| 2026-08-03 | Earnings deck | Q2 2026 Presentation |
| 2026-08-03 | Press release | Vertex Reports Second Quarter 2026 Financial Results |
| 2026-07-07 | Press release | PDF Version |
| 2026-07-06 | Press release | Vertex to Acquire Crinetics Pharmaceuticals |
| 2026-07-06 | Press release | PDF Version |
| 2026-07-06 | Presentation | View Presentation |
| 2026-07-01 | Press release | Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Si |
| 2026-07-01 | Press release | PDF Version |
| 2026-06-11 | Press release | PDF Version |
| 2026-06-11 | Press release | Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the Europe |
| 2026-06-05 | Press release | Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference |
| 2026-06-03 | Press release | Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10 |
| 2026-06-01 | Press release | Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Neph |
| 2026-05-11 | Press release | Vertex to Participate in Upcoming May Investor Conferences |
| 2026-05-06 | Press release | Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Bet |
| 2026-05-04 | Presentation | View Presentation |
| 2026-05-04 | Press release | PDF Version |
| 2026-05-04 | Press release | Vertex Reports First Quarter 2026 Financial Results |
| 2026-04-06 | Press release | Press release |
| 2026-04-01 | Press release | Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medici |
| 2026-03-09 | Press release | Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase |
| 2026-03-05 | Press release | Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructi |
| 2026-03-05 | Press release | Vertex to Participate in Upcoming March Investor Conferences |
| 2026-02-12 | Presentation | View Presentation |
| 2026-02-12 | Press release | PDF Version |
| 2026-02-12 | Press release | Vertex Reports Fourth Quarter and Full Year 2025 Financial Results |
| 2026-01-20 | Press release | Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th |
| 2026-01-11 | Press release | Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings |
| 2025-11-03 | Press release | Vertex Reports Third Quarter 2025 Financial Results |
| 2025-11-03 | Presentation | View Presentation |
| 2025-09-25 | Press release | PDF Version |
| 2025-09-25 | Press release | Vertex Announces Key Advancements Across Kidney Portfolio |
| 2025-08-04 | Press release | PDF Version |
| 2025-08-04 | Press release | Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain |
| 2025-08-04 | Presentation | View Presentation |
| 2025-05-05 | Presentation | Q1 2025 Presentation |
| 2024-11-04 | Press release | PDF Version |
| 2024-11-04 | Press release | Vertex Reports Third Quarter 2024 Financial Results |
| 2024-08-01 | Press release | PDF Version |
| 2024-08-01 | Press release | Vertex Reports Second Quarter 2024 Financial Results |